一、老年弥漫大B细胞淋巴瘤(diffuse largeB cell lymphoma,DLBCL)(初治)临床路径标准 (一)适用对象 第一诊断为初诊DLBCL(ICD-10:C83.3),年龄≥60岁。 (二)诊断依据 根据2022年修订的第5版WHO淋巴组织肿瘤分类。 1.临床表现:主要表现为...
B-cell CLL/lymphoma 2doi:10.1007/978-3-642-16483-5_547BCL2Springer Berlin Heidelberg
Patients with an ICD-10-CM diagnosis for DLBCL after October 2015 and no prior ICD-9-CM diagnosis for unspecified DLBCL or primary mediastinal large B-cell lymphoma (PMBCL) where classified as incident; those with such codes were classified as prevalent. An adapted algorithm identified lines of...
C84.40 -hyphen C84.49 Peripheral T cell lymphoma, not classified [receiving methotrexate or pralatrexate (Folotyn)] C84.60 -hyphen C84.79 Anaplastic large cell lymphoma [receiving methotrexate or pralatrexate (Folotyn)] C84.A0 -hyphen C86.6 Cutaneous T-hyphencell lymphoma unspecified, other mature T/...
The therapeutic strategy for relapsed or refractory patients with diffuse large B-cell lymphoma (DLBL) remains challenging yet. Salvage therapy has been tried for these patients according to their clinical status. We studied ICD (irinotecan, cisplatin and dexamethasone) regimen as salvage chemotherapy ...
纤连蛋白包覆的金属-多酚网络通过增强铁死亡介导的ICD实现肿瘤的化学/化学动力学/免疫协同治疗(Fibronectin-Coated Metal−Phenolic Networksfor Cooperative Tumor Chemo-/Chemodynamic/Immune Therapy viaEnhanced Ferroptosis-Mediated ImmunogenicCell Death) 文献64、 European Radiology 2023-05 IF...
(2008) Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. Cancer Chemotherapy and Pharmacology 62 , 299-304 /Kang HJ;Kim WS;Suh C;.Irinotecan plus cisplatin and dexamethasone(ICD)...
摘要: PURPOSE: The therapeutic strategy for relapsed or refractory patients with diffuse large B-cell lymphoma (DLBL) remains challenging yet. Salvage therapy has been tried for these pa... 查看全部>>关键词:International Classification of Diseases Dexamethasone Cisplatin survival aspects 地塞米松 顺铂 ...
To assess the efficacy and toxicity of oral fludarabine in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin lymphoma (B-NHL), we conducted a multicenter phase II study. Patients with relapsed indolent B-NHL with two or fewer prior regimens and up to 16 doses ...